Comparison of Clinical Characteristics and Parameters at Baseline in Patients With Primary Aldosteronism Who Underwent CCT or SIT
| . | Captopril Challenge Test . | Saline Infusion Test . | ||||
|---|---|---|---|---|---|---|
| . | Positive (n = 1912) . | Negative (n = 344) . | P value . | Positive (n = 953) . | Negative (n = 231) . | P value . |
| Age, y | 52 (44–62) | 51 (43–60) | 0.52 | 50 (43–60) | 58 (50–66) | < 0.01 |
| Female, n (%) | 1056 (55.2) | 164 (47.7) | 0.01 | 453 (47.5) | 168 (72.7) | < 0.01 |
| Body mass index | 24.2 (21.8–27.0) | 25.2 (23.0–28.0) | < 0.01 | 24.6 (22.2–27.7) | 23.5 (21.4–25.6) | < 0.01 |
| Systolic BP, mmHg | 140 (129–152) | 140 (130–151) | 0.85 | 140 (129–150) | 140 (128–149) | 0.39 |
| Diastolic BP, mmHg | 87 (78–96) | 87 (80–97) | 0.24 | 88 (79–96) | 83 (74–91) | < 0.01 |
| Serum potassium, mEq/L | 3.8 (3.4–4.1) | 3.9 (3.6–4.1) | < 0.01 | 3.7 (3.4–4.0) | 4.0 (3.8–4.2) | < 0.01 |
| Hypokalemia, n (%) | 790 (41.3) | 83 (24.1) | < 0.01 | 429 (45.0) | 23 (10.0) | < 0.01 |
| Oral potassium supplements, n (%) | 425 (22.2) | 27 (7.8) | < 0.01 | 235 (24.7) | 4 (1.7) | < 0.01 |
| eGFR | 78.4 (67.1–91.0) | 78.8 (68.5–91.3) | 0.66 | 78.3 (67.2–91.2) | 77.3 (69.2–89.7) | 0.94 |
| PAC, ng/dL | 18.2 (12.9–28.6) | 17.0 (12.7–23.4) | 0.01 | 20.1 (14.5–29.2) | 12.9 (10.1–17.2) | < 0.01 |
| PRA, ng/mL/h | 0.3 (0.2–0.4) | 0.5 (0.4–0.7) | < 0.01 | 0.3 (0.2–0.5) | 0.3 (0.2–0.4) | < 0.05 |
| ARR | 63.2 (39.3–123.8) | 32.1 (25.1–44.6) | < 0.01 | 61.0 (36.8–118.0) | 43.8 (31.5–69.7) | < 0.01 |
| Adrenal nodule(s) on CT, n (%) | 726 (38.0) | 72 (20.9) | < 0.01 | 323 (33.9) | 53 (22.9) | < 0.01 |
| Unilateral PA, n (%) | 517 (27.0) | 21 (6.1) | < 0,01 | 250 (26.2) | 6 (2.6) | < 0.01 |
| CCT pos/neg, n SIT pos/neg, n FUT pos/neg, n | 1,912/0 754/203 1,076/110 | 0/344 181/26 230/ 57 | - | 754/181 953/0 468/118 | 203/26 0/231 147/13 | - |
| . | Captopril Challenge Test . | Saline Infusion Test . | ||||
|---|---|---|---|---|---|---|
| . | Positive (n = 1912) . | Negative (n = 344) . | P value . | Positive (n = 953) . | Negative (n = 231) . | P value . |
| Age, y | 52 (44–62) | 51 (43–60) | 0.52 | 50 (43–60) | 58 (50–66) | < 0.01 |
| Female, n (%) | 1056 (55.2) | 164 (47.7) | 0.01 | 453 (47.5) | 168 (72.7) | < 0.01 |
| Body mass index | 24.2 (21.8–27.0) | 25.2 (23.0–28.0) | < 0.01 | 24.6 (22.2–27.7) | 23.5 (21.4–25.6) | < 0.01 |
| Systolic BP, mmHg | 140 (129–152) | 140 (130–151) | 0.85 | 140 (129–150) | 140 (128–149) | 0.39 |
| Diastolic BP, mmHg | 87 (78–96) | 87 (80–97) | 0.24 | 88 (79–96) | 83 (74–91) | < 0.01 |
| Serum potassium, mEq/L | 3.8 (3.4–4.1) | 3.9 (3.6–4.1) | < 0.01 | 3.7 (3.4–4.0) | 4.0 (3.8–4.2) | < 0.01 |
| Hypokalemia, n (%) | 790 (41.3) | 83 (24.1) | < 0.01 | 429 (45.0) | 23 (10.0) | < 0.01 |
| Oral potassium supplements, n (%) | 425 (22.2) | 27 (7.8) | < 0.01 | 235 (24.7) | 4 (1.7) | < 0.01 |
| eGFR | 78.4 (67.1–91.0) | 78.8 (68.5–91.3) | 0.66 | 78.3 (67.2–91.2) | 77.3 (69.2–89.7) | 0.94 |
| PAC, ng/dL | 18.2 (12.9–28.6) | 17.0 (12.7–23.4) | 0.01 | 20.1 (14.5–29.2) | 12.9 (10.1–17.2) | < 0.01 |
| PRA, ng/mL/h | 0.3 (0.2–0.4) | 0.5 (0.4–0.7) | < 0.01 | 0.3 (0.2–0.5) | 0.3 (0.2–0.4) | < 0.05 |
| ARR | 63.2 (39.3–123.8) | 32.1 (25.1–44.6) | < 0.01 | 61.0 (36.8–118.0) | 43.8 (31.5–69.7) | < 0.01 |
| Adrenal nodule(s) on CT, n (%) | 726 (38.0) | 72 (20.9) | < 0.01 | 323 (33.9) | 53 (22.9) | < 0.01 |
| Unilateral PA, n (%) | 517 (27.0) | 21 (6.1) | < 0,01 | 250 (26.2) | 6 (2.6) | < 0.01 |
| CCT pos/neg, n SIT pos/neg, n FUT pos/neg, n | 1,912/0 754/203 1,076/110 | 0/344 181/26 230/ 57 | - | 754/181 953/0 468/118 | 203/26 0/231 147/13 | - |
Abbreviations: BP, blood pressure; CCT, captopril challenge test; CT, computed tomography; eGFR, estimated glomerular filtration rate; FUT, furosemide upright test; neg, negative; PA, primary aldosteronism; pos, positive; SIT, saline infusion test.
Comparison of Clinical Characteristics and Parameters at Baseline in Patients With Primary Aldosteronism Who Underwent CCT or SIT
| . | Captopril Challenge Test . | Saline Infusion Test . | ||||
|---|---|---|---|---|---|---|
| . | Positive (n = 1912) . | Negative (n = 344) . | P value . | Positive (n = 953) . | Negative (n = 231) . | P value . |
| Age, y | 52 (44–62) | 51 (43–60) | 0.52 | 50 (43–60) | 58 (50–66) | < 0.01 |
| Female, n (%) | 1056 (55.2) | 164 (47.7) | 0.01 | 453 (47.5) | 168 (72.7) | < 0.01 |
| Body mass index | 24.2 (21.8–27.0) | 25.2 (23.0–28.0) | < 0.01 | 24.6 (22.2–27.7) | 23.5 (21.4–25.6) | < 0.01 |
| Systolic BP, mmHg | 140 (129–152) | 140 (130–151) | 0.85 | 140 (129–150) | 140 (128–149) | 0.39 |
| Diastolic BP, mmHg | 87 (78–96) | 87 (80–97) | 0.24 | 88 (79–96) | 83 (74–91) | < 0.01 |
| Serum potassium, mEq/L | 3.8 (3.4–4.1) | 3.9 (3.6–4.1) | < 0.01 | 3.7 (3.4–4.0) | 4.0 (3.8–4.2) | < 0.01 |
| Hypokalemia, n (%) | 790 (41.3) | 83 (24.1) | < 0.01 | 429 (45.0) | 23 (10.0) | < 0.01 |
| Oral potassium supplements, n (%) | 425 (22.2) | 27 (7.8) | < 0.01 | 235 (24.7) | 4 (1.7) | < 0.01 |
| eGFR | 78.4 (67.1–91.0) | 78.8 (68.5–91.3) | 0.66 | 78.3 (67.2–91.2) | 77.3 (69.2–89.7) | 0.94 |
| PAC, ng/dL | 18.2 (12.9–28.6) | 17.0 (12.7–23.4) | 0.01 | 20.1 (14.5–29.2) | 12.9 (10.1–17.2) | < 0.01 |
| PRA, ng/mL/h | 0.3 (0.2–0.4) | 0.5 (0.4–0.7) | < 0.01 | 0.3 (0.2–0.5) | 0.3 (0.2–0.4) | < 0.05 |
| ARR | 63.2 (39.3–123.8) | 32.1 (25.1–44.6) | < 0.01 | 61.0 (36.8–118.0) | 43.8 (31.5–69.7) | < 0.01 |
| Adrenal nodule(s) on CT, n (%) | 726 (38.0) | 72 (20.9) | < 0.01 | 323 (33.9) | 53 (22.9) | < 0.01 |
| Unilateral PA, n (%) | 517 (27.0) | 21 (6.1) | < 0,01 | 250 (26.2) | 6 (2.6) | < 0.01 |
| CCT pos/neg, n SIT pos/neg, n FUT pos/neg, n | 1,912/0 754/203 1,076/110 | 0/344 181/26 230/ 57 | - | 754/181 953/0 468/118 | 203/26 0/231 147/13 | - |
| . | Captopril Challenge Test . | Saline Infusion Test . | ||||
|---|---|---|---|---|---|---|
| . | Positive (n = 1912) . | Negative (n = 344) . | P value . | Positive (n = 953) . | Negative (n = 231) . | P value . |
| Age, y | 52 (44–62) | 51 (43–60) | 0.52 | 50 (43–60) | 58 (50–66) | < 0.01 |
| Female, n (%) | 1056 (55.2) | 164 (47.7) | 0.01 | 453 (47.5) | 168 (72.7) | < 0.01 |
| Body mass index | 24.2 (21.8–27.0) | 25.2 (23.0–28.0) | < 0.01 | 24.6 (22.2–27.7) | 23.5 (21.4–25.6) | < 0.01 |
| Systolic BP, mmHg | 140 (129–152) | 140 (130–151) | 0.85 | 140 (129–150) | 140 (128–149) | 0.39 |
| Diastolic BP, mmHg | 87 (78–96) | 87 (80–97) | 0.24 | 88 (79–96) | 83 (74–91) | < 0.01 |
| Serum potassium, mEq/L | 3.8 (3.4–4.1) | 3.9 (3.6–4.1) | < 0.01 | 3.7 (3.4–4.0) | 4.0 (3.8–4.2) | < 0.01 |
| Hypokalemia, n (%) | 790 (41.3) | 83 (24.1) | < 0.01 | 429 (45.0) | 23 (10.0) | < 0.01 |
| Oral potassium supplements, n (%) | 425 (22.2) | 27 (7.8) | < 0.01 | 235 (24.7) | 4 (1.7) | < 0.01 |
| eGFR | 78.4 (67.1–91.0) | 78.8 (68.5–91.3) | 0.66 | 78.3 (67.2–91.2) | 77.3 (69.2–89.7) | 0.94 |
| PAC, ng/dL | 18.2 (12.9–28.6) | 17.0 (12.7–23.4) | 0.01 | 20.1 (14.5–29.2) | 12.9 (10.1–17.2) | < 0.01 |
| PRA, ng/mL/h | 0.3 (0.2–0.4) | 0.5 (0.4–0.7) | < 0.01 | 0.3 (0.2–0.5) | 0.3 (0.2–0.4) | < 0.05 |
| ARR | 63.2 (39.3–123.8) | 32.1 (25.1–44.6) | < 0.01 | 61.0 (36.8–118.0) | 43.8 (31.5–69.7) | < 0.01 |
| Adrenal nodule(s) on CT, n (%) | 726 (38.0) | 72 (20.9) | < 0.01 | 323 (33.9) | 53 (22.9) | < 0.01 |
| Unilateral PA, n (%) | 517 (27.0) | 21 (6.1) | < 0,01 | 250 (26.2) | 6 (2.6) | < 0.01 |
| CCT pos/neg, n SIT pos/neg, n FUT pos/neg, n | 1,912/0 754/203 1,076/110 | 0/344 181/26 230/ 57 | - | 754/181 953/0 468/118 | 203/26 0/231 147/13 | - |
Abbreviations: BP, blood pressure; CCT, captopril challenge test; CT, computed tomography; eGFR, estimated glomerular filtration rate; FUT, furosemide upright test; neg, negative; PA, primary aldosteronism; pos, positive; SIT, saline infusion test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
